Vertex Pharmaceuticals Takes Lead Over Amgen in Healthcare Sector
When considering two prominent healthcare stocks for investment in 2026, Amgen and Vertex Pharmaceuticals stand out. Amgen serves a broad patient base across oncology and inflammation, while Vertex focuses on transformative therapies for rare diseases like cystic fibrosis.
Amgen operates as a global biotechnology powerhouse, with revenue reaching nearly $36.7 billion in FY 2025, representing a roughly 9.9% increase from the prior year. The company generated net income of close to $7.7 billion during the same period, with a net margin of approximately 21%. Amgen's balance sheet shows a debt-to-equity ratio of about 6.3x and a current ratio of around 1.1x.
Vertex Pharmaceuticals has built a dominant position in cystic fibrosis treatment, providing life-saving medicines to patients worldwide. The company is expanding into new areas like sickle cell disease through its gene therapy, CASGEVY. Vertex's focus on high-need, rare diseases allows for significant pricing power and a relatively loyal customer base.
A key difference between the two companies lies in their risk profiles. Amgen faces challenges from government and commercial pricing pressures, while Vertex is highly dependent on its cystic fibrosis medicines and carries the uncertainty of drug development.